XCUR

Exicure

--

--(--)

Market Open: --

--

--(--)

Post-Market: --

Signals Analysis

Buy signal 0

Sell signal 3

Bearish Engulfing

Price Hits New Low

Price Hits 52-week low

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

--

Prev.Close

--

%Range

--

Turnover

--

Avg Vol(4W)

--

Market Cap

--

Div.Yield

--

P/E(TTM)

--

EPS(TTM)

--

Beta

--

Free Float

--

Shares Outstanding

--

%Turnover

--

P/E(DYN)

--

P/B

--

BVPS

--

High

--

Low

--

52 Week High

--

52 Week Low

--

About XCUR

Exicure, Inc.

An early-stage biotechnology company that developing nucleic acid therapies targeting RNA to address neurological disorders and hair loss disorders

Industry

Pharmaceutical

Established Date

07/09/2015

Listing Date

07/31/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

7

Fiscal Year Ends

12-31

Website

www.exicuretx.com

Security Type

Common stock

Office address

2430 N. Halsted St., Chicago, IL 60614

Business

--

Introduction

Exicure, Inc., was founded on July 9, 2015. The company is a clinical-stage biotechnology company that develops treatments for immuno-oncology, inflammatory diseases and genetic diseases based on its proprietary spherical nucleic acid (SNA) technology.

Company Financials

EPS

XCUR has released its 2023 Q2 earnings. EPS was reported at -0.68, versus the expected 0.00, missing expectations. The chart below visualizes how XCUR has performed over recent quarters, highlighting trends in earnings surprises.